cGMP Facility and Infrastructure

State-of-the-art cGMP facility designed for gene therapy and vaccine production

With an exponential increase in demand for cGMP Plasmid DNA, Akron launched a pDNA manufacturing facility in early 2020 to accelerate clinical and commercial development of advanced therapies.

Akron’s new state-of-the art-facility raises the bar on quality and safety by integrating Cytiva’s flexible, single-use FlexFactory and TrackWise Digital Quality Management System to enable cGMP-compliant production for both ex vivo and in vivo applications.

Akron's Upstream pDNA Suite Animation

Akron's Small Downstream pDNA Suite Animation

Akron's Large Downstream pDNA Suite Animation

Facility Features:

  • LARGE FOOTPRINT WITH EXPANSION CAPACITY – New 60,000 sq. ft. facility with 50,000 sq. ft. expansion currently underway
  • MULTIPLE CLEANROOMS – Several cleanrooms with independent air handling systems (11 AHUs) for segregation control into multiple zones (15,000 sq. ft.)
  • USP WATER FOR INJECTION – WFI distribution loop supplied by Evoqua Puritas VRx with CDILX producing 15 L/min
  • CGMP QUALITY CONTROL LABORATORY – Full suite of pDNA-centered analytical development, qualification, and validation capabilities in-house


  • CYTIVA FLEXFACTORY – 50L and 200L Disposable Bioreactors XDR (MO) from Cytiva for application- and program-appropriate batch size
  • ÄKTA DOWNSTREAM – ÄKTA Pilot systems for process development and ÄKTA Ready single-use liquid chromatography systems for scale-up and manufacturing

An Akron specialist will be in touch with you within 24 hours

*Indicates required field

By clicking submit below, you consent to allow Akron Biotech to store and process the personal information submitted above to provide you the content requested. For more information on our privacy practices and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.